Patents by Inventor Xiaochun WAN

Xiaochun WAN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Human sDR5-fc recombinant fusion protein and application thereof
    Patent number: 11220533
    Abstract: An sDR5-Fc recombinant fusion protein having amino acid sequence of SEQ ID NO: 2 and a gene encoding the protein and having a nucleotide sequence as shown in SEQ ID NO: 1 are provided. Further, applications of the protein and the gene in the preparation of medicament for preventing and treating autoimmune hepatitis or drug-induced liver injury are provided.
    Type: Grant
    Filed: July 11, 2016
    Date of Patent: January 11, 2022
    Assignee: SHENZHEN ZHONGKE AMSHENN PHARMACEUTICAL CO., LTD.
    Inventors: Xiaochun Wan, Junxin Li, Qian Chen, Qingmei Zhang
  • Human sDR5-Fc Recombinant Fusion Protein and Application Thereof
    Publication number: 20190352354
    Abstract: An sDR5-Fc recombinant fusion protein having amino acid sequence of SEQ ID NO: 2 and a gene encoding the protein and having a nucleotide sequence as shown in SEQ ID NO: 1 are provided. Further, applications of the protein and the gene in the preparation of medicament for preventing and treating autoimmune hepatitis or drug-induced liver injury are provided.
    Type: Application
    Filed: July 11, 2016
    Publication date: November 21, 2019
    Applicant: SHENZHEN ZHONGKE AMSHENN PHARMACEUTICAL CO., LTD.
    Inventors: Xiaochun WAN, Junxin LI, Qian CHEN, Qingmei ZHANG
  • C-Rel-specific siRNA and its use for preventing and treating autoimmune psoriasis
    Patent number: 10081810
    Abstract: The present invention provides a c-Rel-specific siRNA and its use for preventing and treating autoimmune psoriasis. In particular, the c-Rel-specific siRNAs have sequences as shown in SEQ ID Nos. 1-2 or SEQ ID Nos. 3-4. In the present invention, small interfering RNA (siRel) specific to c-Rel are employed to inhibit c-Rel biosynthesis, and prevent and treat autoimmune psoriasis by inhibiting inflammatory factors relating to IL-23/IL-17A inflammatory axis.
    Type: Grant
    Filed: August 18, 2017
    Date of Patent: September 25, 2018
    Assignees: SHENZHEN INSTITUTES OF ADVANCED TECHNOLOGY, THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Qingguo Ruan, Youhai H. Chen, Tingting Fan, Yifan Ma, Lintao Cai, Shaowen Wang, Xiaochun Wan
  • C-REL-SPECIFIC SIRNA AND ITS USE FOR PREVENTING AND TREATING AUTOIMMUNE PSORIASIS
    Publication number: 20180002698
    Abstract: The present invention provides a c-Rel-specific siRNA and its use for preventing and treating autoimmune psoriasis. In particular, the c-Rel-specific siRNAs have sequences as shown in SEQ ID Nos. 1-2 or SEQ ID Nos. 3-4. In the present invention, small interfering RNA (siRel) specific to c-Rel are employed to inhibit c-Rel biosynthesis, and prevent and treat autoimmune psoriasis by inhibiting inflammatory factors relating to IL-23/IL-17A inflammatory axis.
    Type: Application
    Filed: August 18, 2017
    Publication date: January 4, 2018
    Inventors: Qingguo RUAN, Youhai H. CHEN, Tingting FAN, Yifan MA, Lintao CAI, Shaowen WANG, Xiaochun WAN